-
Mallinckrodt Rips Higher After Company Confirms $1.6B Opioid Litigation Settlement
Tuesday, February 25, 2020 - 11:03am | 440Read More...Mallinckrodt PLC (NYSE: MNK) shares are ripping higher Tuesday after the company announced a global opioid settlement agreement that limits its payout to $1.6 billion and it aslo reported better-than-expected fourth-quarter results. Opioid Settlement Clinched, Generics Business To File For Chapter...
-
Option Trader Makes Aggressive Bearish Play On Mallinckrodt
Wednesday, July 24, 2019 - 12:44pm | 629Read More...Mallinckrodt PLC (NYSE: MNK) shares are down 32.4% year to date, but a series of unusually large options trades Wednesday morning suggests at least one trader thinks there may be even more downside ahead. The Trades On Wednesday at around 9:46 a.m., Benzinga Pro subscribers were alerted to a...
-
Shkreli: Mallinckrodt Is A Terrible Short
Wednesday, March 22, 2017 - 11:06am | 325Read More...A day after Imprimis Pharmaceuticals Inc (NASDAQ: IMMY) announced plans to develop a lower-priced alternative to Mallinckrodt PLC (NYSE: MNK)’s HP Acthar Gel, Martin Shkreli told Benzinga the proliferating market shorts against Mallinckrodt are “much ado about nothing.” “...
-
Martin Shkreli: Mallinckrodt Will Be Punished
Wednesday, January 18, 2017 - 5:23pm | 364Read More...Following a report exposing Martin Shkreli as a whistleblower against Mallinckrodt PLC (NYSE: MNK), Shkreli told Benzinga that the Federal Trade Commission's new lawsuit is just. “Questcor [Mallinckrodt subsidiary] stopped me from competing with their very high-priced drug which made...
-
Mallinckrodt Reports Better-Than-Expected Q1, Raises Guidance
Tuesday, February 2, 2016 - 8:54am | 263Read More...Shares of Mallinckrodt PLC (NYSE: MNK) were trading higher by nearly 6 percent early Tuesday morning after the company reported its first quarter results. Mallinckrodt earned $2.09 per share in the first quarter on revenue of $914.80 million. Wall Street analysts were expecting the company to...
-
Questcor Pharmaceuticals Plunges on U.S. Government Investigation
Monday, September 24, 2012 - 3:24pm | 326Read More...Last week, Questcor Pharmaceuticals (NASDAQ: QCOR) was among the most volatile stocks on the Nasdaq exchange after insurer Aetna (NYSE: AET) said that it was limiting coverage of the company's Athcar Gel drug used for the treatment of multiple sclerosis. The news sent QCOR plunging last Wednesday,...
-
Questcor Plunging During Investor Conference; Bank of America Says Buy
Friday, July 13, 2012 - 2:29pm | 252Read More...Shares of Questcor Pharmaceuticals (NASDAQ: QCOR) have been plunging throughout Friday's trading session and were recently sitting near session lows, down around 7%. The company is presenting at JMP Securities Healthcare conference today. Questcor discussed the mechanism of action and unique...
